Abstract
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m−2, 5-fluorouracil 500 mg m−2, epidoxorubicin 35 mg m−2, 6S stereoisomer of leucovorin 250 mg m−2 and glutathione 1.5 mg m−2, supported by a daily administration of lenograstim at a dose of 5 μg kg−1. Nineteen patients were men and three were women. Median age was 63 years (range 47–70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott–Huskisson scale of 27.6 ± 23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0–26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott–Huskisson scale of 12.3 ± 18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. © 1999 Cancer Research Campaign
Keywords: pancreatic cancer, intensive chemotherapy, palliation
Full Text
The Full Text of this article is available as a PDF (62.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahlgren J. D. Chemotherapy for pancreatic carcinoma. Cancer. 1996 Aug 1;78(3 Suppl):654–663. doi: 10.1002/(SICI)1097-0142(19960801)78:3<654::AID-CNCR46>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- André T., Lotz J. P., Bouleuc C., Azzouzi K., Houry S., Hannoun L., See J., Esteso A., Avenin D., Izrael V. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol. 1996 Feb;7(2):173–178. doi: 10.1093/oxfordjournals.annonc.a010545. [DOI] [PubMed] [Google Scholar]
- Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
- Carmichael J., Fink U., Russell R. C., Spittle M. F., Harris A. L., Spiessi G., Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996 Jan;73(1):101–105. doi: 10.1038/bjc.1996.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cascinu S., Labianca R., Alessandroni P., Marcellini M., Silva R. R., Pancera G., Testa E., Martignoni G., Barni S., Frontini L. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol. 1997 Nov;15(11):3313–3319. doi: 10.1200/JCO.1997.15.11.3313. [DOI] [PubMed] [Google Scholar]
- Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1994 Dec;12(12):2687–2693. doi: 10.1200/JCO.1994.12.12.2687. [DOI] [PubMed] [Google Scholar]
- Glimelius B., Hoffman K., Sjödén P. O., Jacobsson G., Sellström H., Enander L. K., Linné T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996 Aug;7(6):593–600. doi: 10.1093/oxfordjournals.annonc.a010676. [DOI] [PubMed] [Google Scholar]
- Lionetto R., Pugliese V., Bruzzi P., Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995 Jun;31A(6):882–887. doi: 10.1016/0959-8049(94)00445-5. [DOI] [PubMed] [Google Scholar]
- Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer. 1996 Aug 1;78(3 Suppl):633–638. doi: 10.1002/(SICI)1097-0142(19960801)78:3<633::AID-CNCR44>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
- Palmer K. R., Kerr M., Knowles G., Cull A., Carter D. C., Leonard R. C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994 Jun;81(6):882–885. doi: 10.1002/bjs.1800810629. [DOI] [PubMed] [Google Scholar]
- Rothenberg M. L., Abbruzzese J. L., Moore M., Portenoy R. K., Robertson J. M., Wanebo H. J. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996 Aug 1;78(3 Suppl):627–632. doi: 10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
- Schnall S. F., Macdonald J. S. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol. 1996 Apr;23(2):220–228. [PubMed] [Google Scholar]
- Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer. 1993;29A(8):1076–1078. doi: 10.1016/s0959-8049(05)80290-4. [DOI] [PubMed] [Google Scholar]
- Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]